<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10188890</article-id><article-id pub-id-type="pmc">2362731</article-id><article-id pub-id-type="pii">6690232</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Awada</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Punt</surname><given-names>C J A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Piccart</surname><given-names>M J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tellingen</surname><given-names>O Van</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Manen</surname><given-names>L Van</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kerger</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Groot</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wanders</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wagener</surname><given-names>D J Th</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><collab>on behalf of the EORTC Early Clinical Studies Group and EORTC NDDO</collab></contrib><aff id="aff1">Institut Jules Bordet, Institut Jules Bordet, Bd de Waterloo 125, Brussels, 1000, Belgium</aff><aff id="aff2">University Hospital, Geert Grooteplein 8, Box 9101, Nijmegen, 6500 HB Nijmegen, The Netherlands</aff><aff id="aff3">The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX Amsterdam, The Netherlands</aff><aff id="aff4">European Organization for Research and Treatment of Cancer &#x02013; New Drug Development Office, European Organization for Research and Treatment of Cancer, PO Box 7057, Amsterdam, The Netherlands</aff><aff id="aff5">Rotterdam Cancer Institute, Groene Hilledijk 301, Rotterdam, 3075 EA Rotterdam, The Netherlands</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Jules Bordet Institute, Chemotherapy Unit, Rue H&#x000e9;ger-Bordet 1, 1000 Brussels, Belgium</corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>1999</year></pub-date><volume>79</volume><issue>9-10</issue><fpage>1454</fpage><lpage>1461</lpage><history><date date-type="received"><day>20</day><month>04</month><year>1998</year></date><date date-type="rev-recd"><day>31</day><month>08</month><year>1998</year></date><date date-type="accepted"><day>13</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanced solid tumours. Patients received a median of two courses (range 1&#x02013;5) at one of nine dose levels: 24, 48, 96, 130, 150, 170, 210, 250 and 300 &#x003bc;g m<sup>&#x02212;2</sup>. According to NCI-CTC criteria, non-haematological toxicities (grade 1/2) included fever, nausea and vomiting, mucositis and anorexia, none of which was clearly dose related. The dose-limiting toxicity was haematological and consisted mainly of neutropenia and to a lesser extent thrombocytopenia. From the dose level 150 &#x003bc;g m<sup>&#x02212;2</sup>, the haematological toxicity (particularly thrombocytopenia) was delayed in onset, prolonged and cumulative in some patients. In several courses, double WBC nadirs occurred. The maximum tolerated dose for a single course was 300 &#x003bc;g m<sup>&#x02212;2</sup>. From the dose level 170 &#x003bc;g m<sup>&#x02212;2</sup>, the intended dose intensity could not be delivered to most patients receiving &#x0003e; 2 courses owing to cumulative haematological toxicity. The dose level with the best dose intensity for multiple courses was 150 &#x003bc;g m<sup>&#x02212;2</sup>. The pharmacokinetics of Carzelesin and its metabolites (U-76,073; U-76,074) have been established in 31 patients during the first course of treatment using a HPLC method. Carzelesin exhibited linear pharmacokinetics. The concentration of U-76,074 (active metabolite) extended above the lower limit of quantitation (1 ng ml<sup>&#x02212;1</sup>) for short periods of time and only at the higher dose levels. There was no relationship between neutropenia and the AUC of the prodrug Carzelesin, but the presence of detectable plasma levels of the active metabolite U-76,074 was usually associated with a substantial decrease in ANC values. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>Carzelesin</kwd><kwd>phase I</kwd><kwd>alkylating agent</kwd><kwd>pharmacokinetics</kwd><kwd>phamacodynamics</kwd></kwd-group></article-meta></front></article>
